Investment Rating - The investment rating for the pharmaceutical industry is "Recommended" (maintained) [1] Core Insights - Significant transactions are driving the revaluation of innovative value in the pharmaceutical sector, with major deals such as a $60 billion transaction by 3SBio and a $50 billion forecasted deal by CSPC Pharmaceutical Group [3] - The 2025 ASCO conference highlighted ADC, bispecific antibodies, and tri-specific antibodies as key areas of focus, with promising clinical results reported by Chinese companies [4] - Chinese innovative pharmaceutical companies are leading breakthroughs in CAR-T technology, with significant advancements expected in 2025 [6] - The gout treatment market presents substantial potential, with a projected increase in patients in China from 170 million in 2020 to 240 million by 2030 [8] - The oral weight-loss drug market is seeing increased activity from leading companies, with notable collaborations and clinical advancements [10] - The approval of the world's first flu RNA polymerase PB2 protein inhibitor offers new treatment options for flu resistance [12] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 2.21% over the past week, with a weekly increase of 3.30% [28] - Over the past month, the pharmaceutical sector also outperformed the CSI 300 index by 4.57%, with a monthly increase of 6.42% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index currently has a PE (TTM) of 34.03, slightly above the five-year historical average of 32.54 [45] 3. Recent Research Achievements - The research team has published several in-depth reports on various segments of the pharmaceutical industry, highlighting growth trends and market opportunities [48] 4. Recent Industry Policies and News - Recent policy changes include adjustments to tariffs on imported goods from the U.S. and guidelines for the construction and management of geriatric medicine departments [51] - Notable news includes the approval of multiple innovative drugs and clinical trials by various pharmaceutical companies [52][53]

Investment Rating - The investment rating for the pharmaceutical industry is "Recommended" (maintained) [1] Core Insights - Significant transactions are driving the revaluation of innovation value in the pharmaceutical sector, with notable deals such as a $60 billion transaction by 3SBio and a $50 billion forecasted deal by CSPC Pharmaceutical Group [3] - The 2025 ASCO conference highlighted ADC, bispecific antibodies, and tri-specific antibodies as key areas of focus, with promising clinical results reported by Chinese companies [4] - Chinese innovative pharmaceutical companies are leading breakthroughs in CAR-T technology, with significant advancements expected in 2025 [6] - The gout treatment market presents substantial potential, with a projected increase in patients in China from 170 million in 2020 to 240 million by 2030 [8] - The oral weight loss drug market is seeing increased activity from leading companies, with notable collaborations and clinical advancements [10] - The approval of the world's first flu RNA polymerase PB2 protein inhibitor offers new treatment options for flu resistance [12] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 2.21% over the past week, with a weekly increase of 3.30% [28] - Over the past month, the industry also outperformed the CSI 300 index by 4.57%, with a monthly increase of 6.42% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector's current PE (TTM) is 34.03, slightly above the five-year historical average of 32.54 [45] 3. Recent Research Achievements - Recent reports highlight the steady growth of blood products and the acceleration of the import substitution process in inhalation preparations [48] 4. Recent Industry Policies and News - The State Council announced a reduction in tariffs on imports from the U.S., which may impact the pharmaceutical sector [51] - Several innovative drugs have received approval for clinical trials and market entry, indicating a robust pipeline for the industry [52][53] 5. Recommended Companies and Earnings Forecast - Companies recommended for investment include Changchun High & New Technology, Yifan Biotech, and Zhongsheng Pharmaceutical, among others, with a focus on areas such as gout treatment and CAR-T technology [14]

Group 1 - The Hong Kong stock market saw a strong performance in the innovative drug sector, with significant gains in stocks such as Green Leaf Pharmaceutical, United Pharmaceutical, and Lepu Biopharma, all rising over 6% [1] - The total amount of License-out agreements for Chinese innovative drugs is projected to exceed $50 billion in 2024, reaching $51.9 billion, a year-on-year increase of 27.4%, accounting for 30% of the global total in similar transactions [1] - The Hong Kong innovative drug index's price-to-earnings ratio decreased from 64 times on February 21 to 27 times on June 3, indicating a significant reduction in valuation and highlighting attractive investment opportunities [1] Group 2 - The innovative drug ETF (159992) tracks an index that includes leading companies in the innovative drug industry, benefiting from advancements in AI, the international expansion of domestic innovative drugs, and the introduction of new insurance policies for high-priced innovative drugs [2] - The domestic innovative drug sector has shown strong investment value and growth potential due to policy support, technological advancements, and market recognition of high-quality pharmaceutical companies [2] - The shift in the Chinese innovative drug industry from focusing on quantity and speed to quality and innovation has led to improved R&D capabilities and competitive advantages [2]

Summary of Conference Call Records Industry Overview - The focus is on the innovative drug sector, particularly in the context of recent significant transactions and developments in the PD(L)1*VEGF and GLP1 fields [1][2]. Key Points and Arguments PD(L)1*VEGF Dual Antibody Developments - 康方生物 and Summit announced top-line data from the global clinical trial HARMONI for Ivosidenib targeting 2L EGFRm, indicating: - The PD(L)1*VEGF dual antibody shows certain effectiveness in the post-EGFRm mutation line, although the median follow-up time is short, necessitating longer follow-up for evaluation [1] - The HARMONI study validates the consistency of clinical results between China and the U.S. [1] - The FDA stated that statistically significant overall survival benefits are necessary to support the submission for market approval, which will influence Summit's timeline for BLA submission [1] - The primary focus remains on the first-line global clinical results for Ivosidenib [1] Collaboration and Licensing Opportunities - BMS and BNTX are collaborating on the development of PD(L)1*VEGF dual antibodies, with BMS committing to: - An upfront payment of $1.5 billion, $2 billion in non-contingent annual payments, potential milestone payments of $7.6 billion, and a 50:50 cost/profit sharing arrangement [2] - The continuous licensing of PD(L)1*VEGF assets reflects MNCs' optimism regarding these types of drugs, suggesting potential for identifying advantageous subpopulations for clinical benefits [2] - Other companies such as ROG and ABBV are also expected to have demand for similar assets, with domestic firms like 荣昌生物, 宜明昂科, 华海药业, 华兰生物, and 神州细胞 making strategic moves in this area [2] GLP1/GIP Dual Agonist Transactions - Regeneron and Hansoh Pharmaceutical reached a deal for the GLP1/GIP dual agonist, with Regeneron paying an upfront fee of $80 million, $1.93 billion in milestones, and a double-digit sales share [2] - The past year has seen ABBV, REGN, and JNJ entering the diabetes and weight loss market, expanding competition against existing players like LLY, NVO, MSD, ROG, and AZN [2] - The ongoing interest from MNCs in the weight loss sector is expected to lead to a resurgence of new drug developments, particularly following data releases from conferences like ADA [2] Recommended Companies - The following companies are recommended for attention: - 恒瑞医药, 华东医药, 联邦制药, 歌礼制药, 来凯医药 [3] Market Trends - There is optimism regarding the Chinese innovative drug sector due to ongoing licensing activities, which are expected to drive a bullish market trend [4] - MNCs have reiterated their interest in Chinese assets during recent earnings calls, reflecting a strong demand for domestic innovative drugs and low policy sensitivity [4] - The continuous licensing of Chinese innovative drugs is anticipated to lead to a revaluation of overseas valuations [4] - Recommended stocks for Pharma revaluation include 恒瑞医药, 华东医药, 三生制药, 联邦制药, 中国生物制药, 石药集团/新诺威, 先声药业, 康哲药业, 科伦药业; for Biotech global competitiveness: 益方生物, 泽璟制药, 一品红, 百利天恒, 科伦博泰生物, 贝达药业, 信达生物, 百济神州, 再鼎医药, 和黄医药 [4]

整理 | GLP1减重宝典内容团队 近年来，司美格鲁肽凭借强劲的发展势头，迅速崛起为代谢类药物领域的明星产品，距离成为"全球药王"仅一步之遥。诺和诺德公司2024年的 财报显示，司美格鲁肽全系产品在2024年全年实现收入2018.49亿丹麦克朗（约合292.96亿美元），仅以微弱劣势不敌K药。然而， 考虑到司美 格鲁肽正处于高速增长阶段，而K药的增长已逐渐放缓，2025年司美格鲁肽有望登上"全球药王"的宝座 。 不过，司美格鲁肽能否在"全球药王"的位置上长期停留，仍存在不确定性。 未来一段时间内，来自中国的众多司美格鲁肽生物类似药可能会成 为影响市场走向的重要因素。 诺和诺德司美格鲁肽的专利将于2026年到期。 2025年3月31日，华东医药公告称，司美格鲁肽注射液的上市许可申请正式获受理，申报适应症为成人2型糖尿病患者的血糖控制。 2020年10月，中美华东与参股公司重庆派金生物科技有限公司签署合作协议，共同开发及商业化司美格鲁肽注射液。重庆派金负责完成临床前 研究，达到申报中国临床试验申请（IND）的标准；中美华东则负责后续的全球开发、注册及商业化工作。 2022年6月，华东医药的司美格鲁肽注射液2型糖尿 ...

Market Performance - In May, the A-share market experienced fluctuations, peaking at 3400 points before retreating, with the Wande Microplate Index leading the market with a cumulative increase of over 10% [1] - The CSI 2000 index followed with a 4.1% increase, while the ChiNext 50 and ChiNext Index rose by 3.12% and 3.04% respectively [1][2] - The overall performance of the STAR Market indices was poor, with the STAR 100 and STAR 50 declining by 2.84% and 3.5% respectively [1][2] ETF Performance - The "Global Vision, Betting on China" top ten core ETFs reported a 2% increase in May, with a cumulative rise of 4.59% for the year [4] - The Hong Kong Innovative Drug ETF led the monthly performance with a 9.32% increase, and a remarkable 40.69% rise year-to-date [4][9] - The A500 ETF Fund (512050) increased by 1.97% in May, continuing to attract capital with an inflow of 265 million yuan in the first four days of the week [4][5] Investment Outlook - CITIC Securities anticipates a potential bull market for both Hong Kong and A-share markets, with a key entry point expected between the third and fourth quarters [7] - The trend is shifting towards core assets, driven by a surge in A-share companies going public in Hong Kong, which is expected to activate trading in corresponding A-shares [7] - The CSI A500 index is characterized by high market capitalization, profitability, and growth, with an expected return of 22% over the next year, supported by strong earnings growth [8] Pharmaceutical Sector Insights - The recent surge in the Hong Kong innovative drug sector is attributed to multiple factors, including significant licensing agreements and collaborations with multinational pharmaceutical companies [11] - The first quarter of 2025 saw a 180% year-on-year increase in transaction volume for domestic innovative drugs going abroad, indicating a strong international competitive position [11] - The application of AI in drug discovery and clinical trial design is emerging as a new variable, with domestic companies actively developing AI-assisted research platforms [12]

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant recovery in stock prices, attracting attention from brokers for research and investment opportunities [2] - The Tianhong Innovative Drug ETF (517380) has seen a net inflow of 3.6 million yuan, with a current scale of 389 million yuan as of May 26 [1] - The Tianhong ETF is the only product that comprehensively covers the innovative drug sector across A-shares and Hong Kong stocks, with a focus on the "Hengsheng Huasheng Hong Kong Innovative Drug Selected 50" index [1] Group 2 - The innovative drug industry is entering a new cycle of value reassessment due to a combination of policy, industry, and performance factors [2] - Longjiang Securities suggests that the previous valuation methods used during the bear market may no longer be applicable, indicating a need for a re-evaluation of the valuation system for innovative drug companies [2] - There has been significant interest from brokers, with nearly 60 companies in the pharmaceutical and biotechnology sector being researched this month, highlighting the sector's attractiveness [2]

Group 1 - The ASCO conference opening on May 30 will see a record number of presentations from Chinese experts, catalyzing the innovative drug sector [1] - On May 27, the National Medical Products Administration approved the innovative drug Regaglitin Metformin Tablets by Heng Rui Medicine for the treatment of adult type 2 diabetes, highlighting the growing health threat of diabetes [1] - The Hong Kong innovative drug sector is experiencing a significant valuation adjustment, with the Hong Kong innovative drug index's price-to-earnings ratio dropping from 64 times on February 21 to 27 times on May 27, indicating a strong value proposition for investors [1] Group 2 - The Hong Kong innovative drug sector saw a notable increase on May 27, with key stocks such as Junshi Bioscience rising over 17%, and others like Lepu Biopharma and CSPC Pharmaceutical rising over 7%, reflecting strong market interest [1] - The Hong Kong innovative drug ETF (159567) has shown high trading activity, with an average daily trading volume of 859 million yuan over the past five trading days, indicating robust market engagement [1] - The innovative drug ETF (159992) tracks an index that includes leading companies in the innovative drug industry, benefiting from trends such as AI-driven drug development and the expansion of domestic innovative drugs into international markets [2] Group 3 - According to Everbright Securities, the investment value of the innovative drug sector lies in its technological platform advantages and global commercialization potential, driven by changing demographics and policy adjustments [2] - The innovative drug sector is positioned to meet unmet clinical needs and achieve import substitution through technological breakthroughs, thus opening new market opportunities [2] - The high added value and differentiated advantages of innovative drugs enable them to command a higher willingness to pay, especially under supportive policies and market demand [2]

Group 1 - Hong Kong pharmaceutical stocks experienced a collective surge, with notable increases in companies such as CSPC Pharmaceutical Group and United Laboratories, both rising over 7% [1][2] - Other companies like Luye Pharma, Kelun Pharmaceutical, and Innovent Biologics also saw significant gains, with increases exceeding 6% [1][2] - The market is reacting positively to the upcoming 2025 American Society of Clinical Oncology (ASCO) annual meeting, where several innovative drug companies will showcase their research results [2] Group 2 - Analysts suggest that the Chinese innovative drug sector is entering a phase of result realization, with many research advancements expected to drive continued investment interest in the pharmaceutical sector through 2025 [3] - The collaboration between 3SBio and Pfizer regarding the PD-1/VEGF dual antibody SSGJ-707 is seen as a catalyst for Chinese innovative drug companies to accelerate integration into the global industry chain [2]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a strong performance, with notable gains in stocks such as WuXi Biologics, Innovent Biologics, China National Pharmaceutical Group, and others, reflecting a positive trend in the innovative drug market [1][4]. Group 1: Market Performance - The innovative drug ETF (517110) saw an intraday increase of over 2% [1]. - Major pharmaceutical stocks, including WuXi Biologics and Innovent Biologics, rose by more than 2% [1]. Group 2: Catalysts and Developments - A significant catalyst for the sector is the licensing agreement between 3SBio and Pfizer regarding the PD-1/VEGF bispecific antibody SSGJ-707, marking a milestone with an upfront payment exceeding $1 billion, showcasing the competitiveness of Chinese innovative drugs internationally [4]. - The upcoming ASCO conference is expected to highlight numerous original research outcomes from Chinese pharmaceutical companies, indicating their rapid advancement in innovative R&D [4]. Group 3: Industry Fundamentals - The overall net profit of the pharmaceutical sector decreased by 11.4% year-on-year, but the innovative drug segment showed a positive growth of 4.3% [5]. - The success rate for innovative drugs in the upcoming 2024 medical insurance negotiations is projected to exceed 90%, with domestic products accounting for over 70% [5]. - The pharmaceutical industry is expected to benefit from optimized procurement policies, domestic demand recovery, and continuous technological advancements, leading to a potential valuation recovery [5].